Articles, App Notes, Case Studies, & White Papers

  1. Long-Term Container Closure Integrity Testing Of Vial-Stopper-Seal Combinations 9/3/2024

    The study was designed to investigate CCI over a period of 24 months at ambient, ultra-low and cryogenic temperatures for serum-stopper samples and at ambient temperature for lyo-stopper samples.

  2. Masking Bitter Drug Taste In Pediatric Formulations With Microcaps 6/22/2021

    The challenge was developing a taste masked, convenient dosage formulation of a very bitter API for patients two-years old and older undergoing treatment of HIV infection.

  3. Pediatric Dosage Form Development: Program Design And Formulation Development 6/8/2022

    Explore key considerations to successfully bridge from initial concept of pediatric program design and formulation development strategies into later stages of development and through to commercialization.

  4. Using 505(B)(2) To Streamline Approval Of Combination Products 2/2/2023

    In recent years, the quantity of approvals for products and 505(b)(2) applications has risen, causing developers to map out their regulatory strategy as early as possible.

  5. 3D Screen Printing: Enabling A New Generation Of Complex Formulations 3/17/2025

    Screen-Printed Innovative Drug Technology can produce oral, transdermal, and implantable dosage forms while ensuring heterogeneous distribution of active ingredients.

  6. When Glass Vials Fail At Low Temps, Consider A Cyclic Olefin Polymer System

    If the glass vial for a biologic drug experiences breakage, or does not maintain container closure integrity, a cyclic olefin polymer (i.e., Daikyo Crystal Zenith COP) system may be the solution.

  7. Advancing Chronic Care Through GLP‑1 Innovation 1/23/2026

    GLP‑1 therapies are changing injectable care and driving rapid progress in delivery and manufacturing. See how patient needs, emerging tech, and regulations are reshaping chronic treatment.

  8. Q&A: Navigating PFAS In Medical Devices 1/15/2025

    Explore how PFAS in medical devices pose environmental and health concerns, prompting regulatory scrutiny.

  9. Reducing Environmental Impact At All Stages Of The Medicine Journey

    Explore how utilizing technologies like AI and digital twinning can inform decision-making at the R&D stage and how to optimize the delivery of the final drug product to patients with greener logistics.

  10. Understanding The In-Vitro/In-Vivo Relationship (IVIVR): Inhaled Medicinal Products 11/8/2021

    IVIVR modeling leverages in-vitro testing knowledge toward predicting in-vivo testing results, often reducing long-term development costs by facilitating more informed decision-making during drug development.